VahatiCor

Executive Summary

VahatiCor is a privately held medical device company focused on addressing Coronary Microvascular Dysfunction (CMD), a prevalent yet underdiagnosed condition affecting millions of patients with angina-like symptoms but no significant epicardial coronary artery disease. Current treatment options for CMD are limited, often leaving patients with persistent chest pain, shortness of breath, and reduced quality of life. VahatiCor's lead product, the A-FLUX Reducer System, is a minimally invasive implant designed to redistribute cardiac blood flow from healthy to ischemic microvascular territories, thereby relieving symptoms and improving myocardial perfusion. The device leverages a novel approach that could fill a critical unmet need in interventional cardiology, offering a potential breakthrough for a large, underserved patient population. The company, founded in 2019 and based in San Diego, has been advancing the A-FLUX system through clinical studies. While still in early stages, the technology has generated interest for its potential to address a challenging pathophysiology. VahatiCor's next milestones include completing enrollment in its initial clinical trial and gathering safety and efficacy data to support regulatory submissions. If successful, the A-FLUX Reducer could become a standard-of-care device for CMD, opening a new market within the cardiovascular device space. The company's progress and eventual commercial launch will depend on favorable clinical outcomes and the ability to navigate the FDA approval process.

Upcoming Catalysts (preview)

• Q3 2026Completion of pivotal trial enrollment70% success
• Q4 2026FDA IDE approval or breakthrough device designation60% success
• Q2 2027Interim clinical data readout50% success